09.00 Chair’s Welcome

09.15 US Case Law Update: Judicial Decisions Impacting Crystalline Forms Patent Strategy

• Recent decisions suggesting how US courts may view crystalline form patents
• Analysis of Abbott v. Sandoz (Fed. Cir. 2009): Crystalline Forms and Product-by-Process
• Analysis of Sanofi-Synthelabo v. Apotex (Fed. Cir . 2008) and others
• Analysis of Pfizer v. Apotex (Fed. Cir. 2007) and others: Salt Forms
• Designing and implementing effective patent strategies for crystalline form patents

Raymond R. Mandra
Partner, Fitzpatrick, Cella
Harper & Scinto

10.00 UK Judicial Overview

• Analysis of UK decisions
• General trends in the UK decisions
• Recent decisions suggesting how UK courts may view crystalline form patents
• Case law affecting further decisions in the area of Crystalline forms

Alastair Wilson QC
Joint Head of Chambers
Hogarth Chambers

11.15 Polymorph Patenting And The Doctrine Of Inherent Anticipation: The US Perspective

• What is Doctrine of Inherent Anticipation under US law?
• Why inherent anticipation is a key concern to polymorph patenting based on current drug discovery process?
• US cases dealing with inherent anticipation as it relates to polymorphic forms

Rekha Bansal
Patent Attorney
Amgen

12.00 Roundtable Discussion: Process Claims Vs Product Claims

• Identification of key claims in both areas
• Case law in the area: Abbott vs. Sandoz patenting based on current drug discovery process?
• The impact on internal innovators IP strategies A paper on Abbott vs. Sandoz will be provided to aid discussions.

Facilitated by Day One and Two speakers

14.00 A Generics Perspective

• The perspective of the generic company
• International case law – what jurisdictions matter
• Comparison of reasoning of courts in recent high-profile cases
• Is there convergence?

George Moore
Patent Counsel (International)
Apotex

14.45 European Case Law Update

• European case law update (England & Wales; Scotland; Ireland and EPO): the Tibolone case (Ivax & Arrow v Akzo)
• Non pharmaceutical crystalline forms: Tate & Lyle Technology Ltd v Roquette Freres
• Other High court decisions in the last 12 months ( Leo v Sandoz).

Andre Bourgouin
Chief IP Officer
Ipsen

16.00 European Commission, Directorate General For Competition

• Review of the Commission's Final Report from the Pharmaceutical Sector Inquiry
• Applicability of the EC treaty antitrust law to the IPR area (case law)
• Competition law scrutiny according to the Final Report

Dr Filip Borkowski
DG Competition
European Commission

16.45 Chair’s Closing Remarks

17.00 Close Of Conference Day Two